作者
Aaron S. Kelly,Karthik Chandrasekhar Pamidipati,Marianna Rachmiel,Gitanjali Srivastava,Daniel S. Hsia,Claudia K. Fox,Erika Fortes,Lisa McLeod,Madhumita Murphy,Apurva Prakash
摘要
Importance Information on the effects of tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for obesity management in adults with obesity, remains limited in adolescents. Objective To evaluate the efficacy and safety of once-weekly tirzepatide in adolescents with obesity or overweight with at least 1 obesity-related complication. Design, Setting, and Participants This phase 3, randomized, double-blind, 72-week clinical trial was conducted at 31 medical research centers and hospitals in Canada, the Czech Republic, Israel, Italy, Poland, and the US from October 16, 2023, to June 2, 2026, among adolescents aged 12 years to younger than 18 years with obesity or overweight with at least 1 obesity-related complication. Interventions Participants were randomized 2:1 to receive once-weekly subcutaneous tirzepatide, escalated to a maximum tolerated dose (5, 10, or 15 mg), or placebo for 72 weeks, in addition to healthy lifestyle intervention. Main Outcomes and Measures The primary end point was percent change in body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) from baseline to week 72. Key secondary end points included percentages of participants achieving BMI reductions of at least 5%, at least 10%, at least 15%, and at least 20%; changes in BMI SD score; BMI expressed as a percentage of the 95th percentile; and body weight, waist circumference, and physical functioning from baseline to week 72. Safety outcomes included treatment-emergent adverse events, serious adverse events, and discontinuations due to adverse events. Results A total of 160 participants were randomized to receive tirzepatide (n = 109) or placebo (n = 51). Mean (SD) age at baseline was 14.6 (1.6) years, 99 participants (61.9%) were female, mean body weight was 109.7 kg, and mean BMI was 38.6. At week 72, tirzepatide was associated with 18.5% reduction in BMI, compared with 0.5% increase in BMI with placebo, demonstrating superiority over placebo (estimated treatment difference, −19.0 [95% CI, −23.9 to −14.1] percentage points; P < .001). Of 10 key secondary outcomes, all demonstrated statistically significant differences favoring tirzepatide compared with placebo. Overall, 79.6% of tirzepatide-treated participants achieved BMI reduction of at least 5% compared with 28.5% of participants in the placebo group (risk difference, 51.2 [95% CI, 36.3-66.1] percentage points; P < .001). The most common adverse events with tirzepatide treatment were gastrointestinal (mostly mild to moderate). Conclusions and Relevance In adolescents with obesity or overweight with obesity-related complications, tirzepatide, in addition to healthy lifestyle intervention, led to significant reductions in percent change in BMI compared with placebo at 72 weeks. Trial Registration ClinicalTrials.gov Identifier: NCT06075667